Drawing transformation pathways for making use of joint effects of food and energy production with biodiversity agriphotovoltaics and electrified agricultural machinery.

The achievement of the Sustainable Development Goals is being pursued worldwide. While energy production and consumption are to be oriented towards renewable energies, ecologically and socially sustainable agriculture is also a target for science and society. Due to the expansion of renewable energies, agricultural land in particular is the focus of various interest groups, from food production to energy production. In this interdisciplinary study, we show the opportunities and limits of joint synergies from the nexus of food production, energy production, energy consumption, biodiversity protection and social acceptance of renewable energies in a scenario. Biodiversity agriphotovoltaics, i.e. agriphotovoltaics in combination with biodiversity protection measures, such as flower strips, can make a valuable contribution to promoting biotope connectivity in addition to significant energy production. We show this in a GIS-based regional assessment for Lower Saxony in northern Germany. This rough spatial assessment is followed by a modelling of energy production and consumption during the cultivation of a characteristic agricultural field in the loess region of Lower Saxony. Our focus here is on the possibilities of using cable electricity or battery storage for carrying out the cultivation. In an accompanying survey of farmers regarding the use of agriphotovoltaics, we collected and evaluated their prior knowledge, experiences, and attitudes towards this technology. Finally, we show which advantages agriphotovoltaics and electrified agricultural machinery can also have for the sustainable transformation of agriculture and which challenges exist for a truly sustainable use of these technologies.

The efficacy and safety of rifaximin-α: a 2-year observational study of overt hepatic encephalopathy.

BACKGROUND: After 5 years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world setting. METHODS: We carried out prospective identification of all patients using rifaximin-α for overt HE. We assessed hospital resource use, bacterial infections, and adverse events during 6-month episodes before and after rifaximin-α initiation. RESULTS: During 26 months we included 127 patients [71.7% male; median age 60.8 years (interquartile range: 56.2-66.1); median model for end-stage liver disease (MELD) score 15.0 (interquartile range: 12.1-20.4); 98% using lactulose treatment]. When comparing the first 6 months after rifaximin-α initiation with the prior 6 months, HE-related hospital admissions decreased (0.86 to 0.41 admissions/patient; p < 0.001), as well as the mean length of stay (8.85 to 3.79 bed days/admission; p < 0.001). No significant differences were found regarding HE-related intensive care unit admissions (0.09 to 0.06 admission/patient; p = 0.253), stay on the intensive care unit (0.43 to 0.57 bed days/admission; p = 0.661), emergency department visits (0.66 to 0.51 visits/patient; p = 0.220), outpatient clinic visits (2.49 to 3.30 bed visits/patient; p = 0.240), or bacterial infections (0.41 to 0.35 infections/patient; p = 0.523). Adverse events were recorded in 2.4% of patients. CONCLUSIONS: The addition of rifaximin-α to lactulose treatment was associated with a significant reduction in the number and length of HE-related hospitalizations for overt HE. Rifaximin-α treatment was well tolerated.